Key statistics dashboard for Greenwich LifeSciences, Inc. (GLSI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials.
Stock Data
| Price | $15.63 |
| Market Cap | $229M |
| Enterprise Value | $220.5M |
| Beta | 1.53 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -10.15 |
| Price / Book | 73.32 |
| P/S | 0.00 |
| EV/EBITDA | -10.17 |
| EV/Sales | 0.00 |
| EV/FCF | -17.66 |
| P/FCF | -18.37 |
| Earnings Yield | -9.49% |
| FCF Yield | -5.44% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -793.76% |
| Return on Assets | -244.25% |
| Return on Invested Capital | -701.55% |
| Return on Capital Employed | -701.55% |
Financial Health
| Current Ratio | 1.54 |
| Quick Ratio | 1.54 |
| Cash Ratio | 1.54 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.41 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.21 |
| Cash per share | 0.61 |
| FCF per share | -0.85 |
| Tangible Book Value per share | 0.21 |
| Dividend per share | 0.00 |
Related companies: AGEN · ATOS · CGTX · HURA · IMMX · IRD · ONCY
Explore sector: Healthcare · Biotechnology
More sections of GLSI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks